Medicina
Saila
Merck Institute for Science Education
Rahway, Estados UnidosMerck Institute for Science Education-ko ikertzaileekin lankidetzan egindako argitalpenak (5)
2022
-
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 23, Núm. 3, pp. 393-405
-
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
The Lancet Oncology, Vol. 23, Núm. 5, pp. 659-670
2020
-
Pembrolizumab in microsatellite-instability-high advanced colorectal cancer
New England Journal of Medicine, Vol. 383, Núm. 23, pp. 2207-2218
2011
-
Boceprevir for untreated chronic HCV genotype 1 infection
New England Journal of Medicine, Vol. 364, Núm. 13, pp. 1195-1206